AGRANULOCYTOSIS AND MACULOPAPULAR RASH AFTER TREATMENT WITH TICLOPIDINE – CASE REPORT

Abstract

Background. Ticlopidine is one of inhibitors of platelet aggregation indicated for reducing the risk of thrombotic stroke in patients who have experienced thrombotic stroke, ischemic attacks, unstable angina pectoris, coronary artery stenting and peripheral vascular bypass grafting. The weak point of this treatment are many serious adverse effects, the most serious of them being neutropenia.Patient and therapy. We report a case of a 70-years old woman who developed agranulocytosis and skin rash by the end of the 4-week therapy with ticlopidine. After discontinued therapy with ticlopidine and when lenograstim was administered, agranulocytosis, anemia and rash subsided in one week.Conclusions. As ticlopidine is associated with serious complications, its application has to be reserved for those patients who are intolerant to aspirin therapy.

Keywords

• platelet aggregation inhibitor
• neutropenia
• agranulocytosis
• thrombocytopenia
• anemia